Overview

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanoma harboring BRAF or NRAS mutations, histiocytic neoplasms harboring BRAF or NRAS mutations, and other solid tumors harboring BRAF mutations. The study population for the Dose Expansion part of the study comprises adults with recurrent advanced/metastatic NSCLC harboring KRAS non-G12C mutations. All patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

Eligibility

Key Inclusion Criteria:

1. Disease criteria:
   1. Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations.

      Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study.

   2. Dose Escalation cohorts:
      • NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V/G12D) or BRAF (Class I, II, or III) (with Sponsor approval).
      • Melanoma with BRAF (Class I, II, or III) or NRAS mutations.
      • Histiocytic neoplasms with BRAF (Class I, II, or III) or NRAS mutations.
      • Thyroid carcinoma with BRAF (Class I, II, or III) mutations.
      • Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.
      • Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF/MEK inhibitor or local standard-of-care with Sponsor approval.
   3. Dose Expansion cohort:

             Recurrent advanced/metastatic NSCLC with KRAS non-G12C mutations without small cell
             lung cancer transformation with progressive disease confirmed by radiographic
             assessment.
          2. Received prior standard-of-care:
               1. Exhausted all available standard-of-care therapies or, in the opinion of the
                  Investigator, would be unlikely to tolerate or derive clinically meaningful
                  benefit from available standard-of-care therapy.
               2. Patients with eligible tumors harboring BRAF V600E mutations that have received
                  FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF
                  inhibitors combination.
          3. Evaluable or measurable disease in dose escalation and measurable disease only for
             dose expansion cohorts.
          4. Adequate bone marrow and organ function.
          5. Recovered from toxicity to prior anti-cancer therapy.
          6. Appropriate candidate for BDTX-4933 monotherapy.
          7. Life expectancy of >=12 weeks in the opinion of the Investigator.
        Key Exclusion Criteria:
          1. Cancer that has a known MEK1/2 mutation.
          2. Major surgery within 4 weeks of study entry or planned during study.
          3. Ongoing anticancer therapy.
          4. Ongoing radiation therapy.
          5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral
             infection requiring systemic therapy.
          6. Symptomatic spinal cord compression.
          7. Evidence of active malignancy (other than study-specific malignancies) requiring
             systemic therapy within the next 2 years.
          8. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.
          9. Females who are pregnant or breastfeeding.
         10. Actively receiving systemic treatment or direct medical intervention on another
             therapeutic clinical study.
         11. Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.